Since MRS could compete with p16INK4a for binding to CDK4, the stabilizing effect of MRS on CDK4 was more significant in p16INK4a-negative breast cancer cells (Kwon et al., 2018). The gene discussed is CDKN2A; the disease is breast carcinoma.